Novo valuation surpasses Tesla on experimental obesity drug data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. SBUX
3. LEVI
4. NVDA
5. GOOGL
6. USO
7. STZ
8. CRGY
9. AAPL
10. SPY

Go back to Novo valuation surpasses Tesla on experimental obesity drug data

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD Cowen

March 11, 2024 2:03 PM EDT

TD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.

The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More

Jefferies starts Viking Therapeutics (VKTX) at buy on 'scarcity value'

March 7, 2024 1:59 PM EST

Jefferies initiated Viking Therapeutics (NASDAQ: VKTX) with a Buy rating and $110 per share price target in a note Thursday, telling investors the company is a strong mid-stage obesity player with scarcity value.

VKTX is developing subQ/oral VK2735 (GLP-1/GIP) for obesity,... More